SCHEMBL1268692

SCHEMBL1268692

COC1CCS(=O)(=O)CC1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.33
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12156992 0.84
SCHEMBL12156948 0.84
SCHEMBL7701171 0.84
SCHEMBL11159712 0.80 GAA (0.37) GAAALDH1A1MAPTL3MBTL1
SCHEMBL21514155 0.79
SCHEMBL17320540 0.72 GAA (0.30) GAA
SCHEMBL19596733 0.72 GAA (0.30) GAA
SCHEMBL5987177 0.72 ALDH1A1 (0.48) GAAALDH1A1L3MBTL1
SCHEMBL14035754 0.72 L3MBTL1 (0.35) GAAALDH1A1L3MBTL1
SCHEMBL7803296 0.72 GAA (0.31) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991655-B1 COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-04-10 EP claimed
CN-117337297-A Use of SOS1 inhibitors and MTOR inhibitors for the treatment of cancer 锐新医药公司 2024-01-02 CN claimed
US-20240229063-A1 TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF MONSANTO TECHNOLOGY LLC (US) 2024-07-11 US disclosed
EP-4389751-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Kumquat Biosciences Inc. (US) 2024-06-26 EP disclosed
US-11912708-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-02-27 US disclosed
US-20240025862-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-01-25 US disclosed
CN-117337297-A Use of SOS1 inhibitors and MTOR inhibitors for the treatment of cancer 锐新医药公司 2024-01-02 CN disclosed
WO-2023215801-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-11-09 WO disclosed
WO-2023215802-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-11-09 WO disclosed
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-26 US disclosed
WO-2023205701-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-10-26 WO disclosed
US-20060241171-A1 Novel physiologically active substances MICROBIOPHARM JAPAN CO., LTD. (JP) 2006-10-26 US disclosed
US-20060235002-A1 Novel physiologically active substance EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-10-19 US disclosed
US-20060166278-A1 Method for synthesizing sugar chain(s) MITSUBISHI CHEMICAL CORPORATION (JP) 2006-07-27 US disclosed
EP-1640379-A1 METHOD OF SYNTHESIZING SUGAR CHAIN Mitsubishi Chemical Corporation (JP) 2006-03-29 EP disclosed
US-20060009439-A1 Novel physiologically active substances MERCIAN CORPORATION (JP) 2006-01-12 US disclosed
US-20050245514-A1 Novel physiologically active substances MICROBIOPHARM JAPAN CO., LTD. (JP) 2005-11-03 US disclosed
EP-1548121-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-06-29 EP disclosed
EP-1541570-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE MERCIAN CORPORATION (JP) 2005-06-15 EP disclosed
EP-1508570-A1 NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245514-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA GAA 2411/4885ALDH1A1 133/4885MAPT 4789/4885
US-11912708-B2 Macrocyclic heterocycles and uses thereof HRAS, KRAS, TP53 GAA 4116/4885ALDH1A1 4341/4885MAPT 4011/4885
US-20060241171-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA GAA 3376/4885ALDH1A1 108/4885MAPT 4828/4885
US-20060009439-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA GAA 3376/4885ALDH1A1 108/4885MAPT 4828/4885
US-20060235002-A1 Novel physiologically active substance HIF1AN, HIF1A, VEGFA GAA 2570/4885ALDH1A1 119/4885MAPT 4866/4885
US-20240025862-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES PFAS, DDT, NOTUM GAA 659/4885ALDH1A1 103/4885MAPT 2308/4885
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF HRAS, KRAS, TP53 GAA 4116/4885ALDH1A1 4341/4885MAPT 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.